Kalvista Pharmaceuticals, Ltd.
Clinical trials sponsored by Kalvista Pharmaceuticals, Ltd., explained in plain language.
-
New hope for kids with rare swelling disorder
Disease control CompletedThis study tested the safety and effectiveness of a medication called sebetralstat (KVD900) in children aged 2 to 11 with hereditary angioedema (HAE), a rare genetic condition that causes sudden, severe swelling attacks. The trial involved 36 children and aimed to see how well th…
Phase: PHASE3 • Sponsor: KalVista Pharmaceuticals, Ltd. • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC
-
Study measures how fast emergency treatment works for rare swelling disorder
Symptom relief CompletedThis study observed 88 patients with hereditary angioedema (HAE) who already use icatibant to treat sudden swelling attacks. Researchers tracked how quickly symptoms improved and anxiety decreased after taking the medication. The goal was to better understand the real-world effec…
Sponsor: KalVista Pharmaceuticals, Ltd. • Aim: Symptom relief
Last updated Mar 02, 2026 15:27 UTC